{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:10:03Z","timestamp":1747023003981,"version":"3.40.5"},"reference-count":55,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NDT"],"DOI":"10.2147\/ndt.s494229","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T03:50:13Z","timestamp":1747021813000},"page":"1029-1045","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Tolerability of Viloxazine Compared to Placebo on Emotional, Behavioral, and Executive Functioning in Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis"],"prefix":"10.2147","volume":"Volume 21","author":[{"given":"Prapinpatch","family":"Maneeton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benchalak","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanisa","family":"Winichaikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suttipong","family":"Kawilapat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nongluck","family":"Kienngam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-6720","authenticated-orcid":true,"given":"Narong","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"ref1","first-page":"1","author":"Danielson","year":"2024","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5455\/apd.135050","volume":"22","author":"Da\u011fdelen","year":"2021","journal-title":"Alpha Psychiatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5152\/alphapsychiatry.2023.231185","volume":"24","author":"Tan\u0131r","year":"2023","journal-title":"Alpha Psychiatr"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"789982","DOI":"10.3389\/fpsyt.2021.789982","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front Psychiatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40263-023-01023-6","volume":"37","author":"Price","year":"2023","journal-title":"CNS Drugs"},{"key":"ref6","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]","year":"2011"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.v69n0812","volume":"69","author":"Papakostas","year":"2008","journal-title":"J Clin Psychiatr"},{"key":"ref9","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2009"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]","year":"2011"},{"key":"ref12","unstructured":"A Phase I\/IIa, randomized, double-blind study of the safety and efficacy of SPN-812 in adults with ADHD(NCT01107496). ClinicalTrials.gov. 2010. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01107496. Accessed June 05, 2024."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","volume":"36","author":"Nasser","year":"2022","journal-title":"CNS Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"113664","DOI":"10.1016\/j.psychres.2020.113664","volume":"296","author":"Faraone","year":"2021","journal-title":"Psychiatry Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40272-021-00470-2","volume":"23","author":"Faraone","year":"2021","journal-title":"Paediatric Drugs"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/NDT.S312011","volume":"17","author":"Nasser","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14330","volume":"75","author":"Nasser","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1089\/cap.2020.0148","volume":"31","author":"Nasser","year":"2021","journal-title":"J Child & Adol Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"114922","DOI":"10.1016\/j.psychres.2022.114922","volume":"318","author":"Faraone","year":"2022","journal-title":"Psychiatry Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1111\/bcp.15412","volume":"88","author":"Nasser","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e2910","DOI":"10.1002\/brb3.2910","volume":"13","author":"Faraone","year":"2023","journal-title":"Brain Behav"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00787-021-01877-5","volume":"32","author":"Faraone","year":"2023","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/j.jaac.2023.09.337","volume":"62","author":"Findling","year":"2023","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S1092852919000051","volume":"24","author":"Nasser","year":"2019","journal-title":"CNS Spectrums"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1016\/j.jaac.2021.09.414","volume":"60","author":"Nasser","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.jaac.2023.09.130","volume":"62","author":"Findling","year":"2023","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref27","first-page":"1","volume":"14","author":"Singh","year":"2022","journal-title":"J Central Nervous System Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.22201\/fesz.26831422e.2023.5.2.5","volume":"5","author":"Jaasiel L\u00f3pez-Cruz","year":"2023","journal-title":"Casos & Revisiones de Salud"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1177\/10600280231163252","volume":"57","author":"Raible","year":"2023","journal-title":"Ann Pharmacother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"Nasser","year":"2020","journal-title":"Clin Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1087054719836159","volume":"24","author":"Johnson","year":"2020","journal-title":"J Attention Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1017\/S1092852920000310","volume":"25","author":"Nasser","year":"2020","journal-title":"CNS Spectrums"},{"key":"ref33","volume":"25","author":"Nasser","year":"2020","journal-title":"CNS Spectrums"},{"key":"ref34","first-page":"272","volume":"25","author":"Nasser","year":"2020","journal-title":"CNS Spectrums"},{"key":"ref35","first-page":"915","volume":"16","author":"Nasser","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","volume":"41","author":"Nasser","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"ref37","first-page":"43","volume":"51","author":"Nasser","year":"2021","journal-title":"Psychopharmacol Bulletin"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clinthera.2021.01.027","volume":"43","author":"Nasser","year":"2021","journal-title":"Clin Ther"},{"key":"ref39","first-page":"915","volume":"16","author":"Nasser","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref40","first-page":"914","volume":"16","author":"Nasser","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref41","first-page":"914","volume":"16","author":"Nasser","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref42","unstructured":"Evaluation of SPN-812 ER low dose in children with ADHD(NCT03247530). ClinicalTrials.gov. 2017. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03247530. Accessed June 05, 2024."},{"key":"ref43","unstructured":"Evaluation of SPN-812 ER low dose in adolescents with ADHD(NCT03247517). ClinicalTrials.gov. 2017. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03247517. Accessed June 05, 2024."},{"key":"ref44","unstructured":"Evaluation of SPN-812 ER high dose in children with ADHD(NCT03247543). ClinicalTrials.gov. 2017. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03247543. Accessed June 05, 2024."},{"key":"ref45","unstructured":"Evaluation of SPN-812 ER high dose in adolescents with ADHD(NCT03247556). ClinicalTrials.gov. 2017. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03247556. Accessed June 05, 2024."},{"key":"ref46","unstructured":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in preschool-age children with ADHD(NCT04781140). ClinicalTrials.gov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04781140. Accessed June 05, 2024."},{"key":"ref47","unstructured":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in adults with ADHD(NCT04016779). ClinicalTrials.gov. 2019. Available from: https:\/\/clinicaltrials.gov\/show\/NCT04016779. Accessed June 05, 2024."},{"key":"ref48","unstructured":"Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in children with ADHD(NCT02633527). ClinicalTrials.gov. 2015. Available from: https:\/\/clinicaltrials.gov\/show\/NCT02633527. Accessed June 05, 2024."},{"key":"ref49","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/j.jaac.2017.09.367","volume":"56","author":"Johnson","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref50","unstructured":"Classroom study of SPN-812 in children with ADHD(NCT04016792). ClinicalTrials.gov. 2019. Available from: https:\/\/clinicaltrials.gov\/show\/NCT04016792. Accessed June 05, 2024."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.jaac.2020.08.092","volume":"59","author":"Nasser","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref52","first-page":"S170","volume":"58","author":"Nasser","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref53","first-page":"S170","volume":"58","author":"Nasser","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.jaac.2019.08.475","volume":"58","author":"Nasser","year":"2019","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"ref55","first-page":"265","volume":"31","author":"Chun Wong","year":"2019","journal-title":"Psychiatria Danubina"}],"container-title":["Neuropsychiatric Disease and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/102867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/102867","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T03:50:20Z","timestamp":1747021820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/efficacy-and-tolerability-of-viloxazine-compared-to-placebo-on-emotion-peer-reviewed-fulltext-article-NDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":55,"URL":"https:\/\/doi.org\/10.2147\/ndt.s494229","relation":{},"ISSN":["1178-2021"],"issn-type":[{"value":"1178-2021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}